Liver cell carcinoma
ICD-10 C22.0 is a billable code used to indicate a diagnosis of liver cell carcinoma.
Liver cell carcinoma (HCC) is the most common primary malignancy of the liver, often arising in the context of chronic liver disease, particularly cirrhosis. It is characterized by the uncontrolled proliferation of hepatocytes, which can lead to significant morbidity and mortality. The condition is frequently associated with underlying liver diseases such as hepatitis B and C infections, alcoholic liver disease, and non-alcoholic fatty liver disease (NAFLD). Patients with cirrhosis are at a markedly increased risk for developing HCC, with surveillance recommended for those with cirrhosis using imaging techniques and serum alpha-fetoprotein (AFP) levels. Elevated AFP levels can serve as a biomarker for diagnosis and monitoring of HCC progression. Treatment options for liver cell carcinoma may include surgical resection, liver transplantation, and locoregional therapies, depending on the stage of the disease and the underlying liver function. The prognosis for patients with HCC is often poor, particularly in advanced stages, making early detection and intervention critical.
Detailed history of liver disease, imaging results, and AFP levels.
Patients with chronic hepatitis or cirrhosis presenting with new-onset abdominal pain or weight loss.
Ensure documentation reflects the relationship between cirrhosis and HCC, including surveillance protocols.
Staging information, treatment plans, and response to therapy.
Patients undergoing treatment for HCC, including surgical interventions or chemotherapy.
Accurate staging is crucial for treatment decisions and prognosis.
Performed for patients with HCC meeting transplant criteria.
Document the diagnosis, staging, and transplant eligibility criteria.
Hepatology and transplant surgery must coordinate documentation.
Elevated AFP levels can indicate the presence of liver cell carcinoma and are used for diagnosis, monitoring treatment response, and assessing recurrence risk.
